The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Abstract

Introduction: Immune checkpoint inhibitor (ICI) associated diabetes is a harmful adverse event (AE) in patients with cancer following anti-programmed (cell) death protein-1 (PD-1) treatment. There are no available biomarkers able to predict this AE. The primary aim of this study was to investigate C-peptide levels as potential predictor for the occurrence of ICI-related diabetes. The secondary aim was to describe the presence of islet autoantibodies and course of pancreatic enzymes in patients with and without ICI-related diabetes. Methods: From a total of 1318 patients with cancer who started anti-PD-1 treatment 8 cases and 16 controls were studied in this nested case-control study. C-peptide levels, islet autoantibodies, and pancreatic enzymes were measured in prospectively collected blood serum. Results: In cases versus controls, median C-peptide levels were comparable at baseline and before toxicity or at the corresponding time point in controls. No patient had C-peptide levels below reference range before toxicity onset. Two out of eight patients in the ICI-related diabetes group had positive islet autoantibodies, whereas one out of 16 patients in the control group had positive islet autoantibodies. Pancreatic enzymes were elevated before diabetes onset in one patient (13%) and in one control (6%) at the corresponding time point. Conclusions: In patients developing ICI-related diabetes, changes in C-peptide levels, islet autoantibody positivity, and pancreatic enzymes before ICI-related diabetes onset seem comparable to patients without ICI-related diabetes.

Original languageEnglish
Article number113839
Number of pages7
JournalBiomedicine and Pharmacotherapy
Volume156
DOIs
Publication statusPublished - Dec 2022

Bibliographical note

Publisher Copyright: © 2022 The Authors

Fingerprint

Dive into the research topics of 'The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy'. Together they form a unique fingerprint.

Cite this